The US Food and Drug Administration (FDA) has approved glycopyrrolate inhalation solution 25 mcg twice daily for maintenance treatment of airflow obstruction in adults with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. This is the first nebulized long-acting muscarinic antagonist (LAMA) approved by the FDA for the treatment of COPD.